Literature DB >> 19082742

P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?

Praveen V Balimane1, Anthony Marino, Saeho Chong.   

Abstract

The objective was to directly compare the four different "calculation" methods of assessing P-gp inhibition potential using experimental data obtained from approximately 60 structurally diverse internal research and marketed compounds. Bidirectional studies for digoxin (probe for P-gp substrate) were performed with and without test compounds (at 10 microM). Four different calculation methods were applied to the same dataset (raw bidirectional permeability values) to obtain the "percent inhibition of P-gp" for these compounds using the different methods. Significantly different inhibition potential was obtained with the "exact" same experimental dataset depending on the calculation method used. Subsequently, entirely different conclusions regarding the "inhibition potential" of test compound was reached due to the different calculation methods. Based on the direct comparison of these methods, method no. 3 (i.e., inhibition of B to A permeability of digoxin) is recommended as the calculation method ideal during screening stages due to its high throughput amenability. The methodology is capable of rapidly screening compounds with adequate reliability for early stage drug discovery. Method no. 3 provides an abridged version of a bidirectional study that is fully capable of identifying all non-inhibitors (0-20%), moderate inhibitors (20-60%), and potent inhibitors (>60%) and demonstrates high correlation with method no. 1 (inhibition based on both A to B and B to A permeability of digoxin). Nevertheless, method no. 1 might be appropriate for more detailed mechanistic studies required in late stage discovery and development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082742      PMCID: PMC2628205          DOI: 10.1208/s12248-008-9068-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  26 in total

1.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

Review 2.  Assessing the absorption of new pharmaceuticals.

Authors:  I J Hidalgo
Journal:  Curr Top Med Chem       Date:  2001-11       Impact factor: 3.295

Review 3.  Cell culture-based models for intestinal permeability: a critique.

Authors:  Praveen V Balimane; Saeho Chong
Journal:  Drug Discov Today       Date:  2005-03-01       Impact factor: 7.851

Review 4.  Current industrial practices of assessing permeability and P-glycoprotein interaction.

Authors:  Praveen V Balimane; Yong-Hae Han; Saeho Chong
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

Review 5.  Drug interaction studies: study design, data analysis, and implications for dosing and labeling.

Authors:  S-M Huang; R Temple; D C Throckmorton; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

6.  Caco-2 replace or refine?

Authors:  Anna-Lena B Ungell
Journal:  Drug Discov Today Technol       Date:  2004-12

7.  Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

Authors:  Jiunn H Lin
Journal:  Adv Drug Deliv Rev       Date:  2003-01-21       Impact factor: 15.470

8.  Interaction between quinidine and digoxin.

Authors:  E B Leahey; J A Reiffel; R E Drusin; R H Heissenbuttel; W P Lovejoy; J T Bigger
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

9.  Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

10.  Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery.

Authors:  Edward H Kerns; Li Di; Susan Petusky; Michele Farris; Rob Ley; Phil Jupp
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534

View more
  10 in total

1.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

2.  Case Study 7: Transporters Case Studies-In Vitro Solutions for Translatable Outcomes.

Authors:  Sid Bhoopathy; Chris Bode; Vatsala Naageshwaran; Erica Weiskircher-Hildebrandt; Venkata Mukkavilli; Ismael J Hidalgo
Journal:  Methods Mol Biol       Date:  2021

3.  Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Authors:  Joe Bentz; Michael P O'Connor; Dallas Bednarczyk; Joann Coleman; Caroline Lee; Johan Palm; Y Anne Pak; Elke S Perloff; Eric Reyner; Praveen Balimane; Marie Brännström; Xiaoyan Chu; Christoph Funk; Ailan Guo; Imad Hanna; Krisztina Herédi-Szabó; Kate Hillgren; Libin Li; Evelyn Hollnack-Pusch; Masoud Jamei; Xuena Lin; Andrew K Mason; Sibylle Neuhoff; Aarti Patel; Lalitha Podila; Emile Plise; Ganesh Rajaraman; Laurent Salphati; Eric Sands; Mitchell E Taub; Jan-Shiang Taur; Dietmar Weitz; Heleen M Wortelboer; Cindy Q Xia; Guangqing Xiao; Jocelyn Yabut; Tetsuo Yamagata; Lei Zhang; Harma Ellens
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

4.  In Vitro Evaluation of P-gp-Mediated Drug-Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model.

Authors:  Sonia Saib; Sophie Hodin; Valérie Bin; Edouard Ollier; Xavier Delavenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-12-22       Impact factor: 2.441

5.  In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.

Authors:  Xiaoyan Chu; Grace Hoyee Chan; Robert Houle; Meihong Lin; Jocelyn Yabut; Christine Fandozzi
Journal:  AAPS J       Date:  2022-03-21       Impact factor: 4.009

Review 6.  Population-based mechanistic prediction of oral drug absorption.

Authors:  Masoud Jamei; David Turner; Jiansong Yang; Sibylle Neuhoff; Sebastian Polak; Amin Rostami-Hodjegan; Geoffrey Tucker
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

Review 7.  Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours.

Authors:  C Li; B-Q Sun; X-D Gai
Journal:  Clin Transl Oncol       Date:  2014-03-19       Impact factor: 3.405

8.  A novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transporters.

Authors:  Michael O'Connor; Caroline Lee; Harma Ellens; Joe Bentz
Journal:  Pharmacol Res Perspect       Date:  2014-12-02

9.  Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.

Authors:  Jee Sun Min; Doyun Kim; Jung Bae Park; Hyunjin Heo; Soo Hyeon Bae; Jae Hong Seo; Euichaul Oh; Soo Kyung Bae
Journal:  Drug Des Devel Ther       Date:  2016-09-14       Impact factor: 4.162

Review 10.  Prediction of drug-ABC-transporter interaction--Recent advances and future challenges.

Authors:  Floriane Montanari; Gerhard F Ecker
Journal:  Adv Drug Deliv Rev       Date:  2015-03-11       Impact factor: 15.470

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.